Tonix Pharmaceuticals Holding Corp
Research Tonix Pharmaceuticals Holding Corp (TNXP) on Bullrun: market cap USD 79.60M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerTNXP
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 79.60M
- Financial periodQ3 2026
- RevenueUSD 17.23M
- Net income-USD 53.33M
- Free cash flow-USD 41.68M
- Gross margin92.7%
Valuation Snapshot
latest market cap is USD 79.60M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 13.11M | -USD 124.02M | -USD 103.21M | 49.3% | -14.57 | USD 207.64M | USD 1.31M | USD 245.15M |
| FY2024 | USD 10.09M | -USD 130.04M | -USD 61.05M | 23.1% | -176.6 | USD 98.78M | USD 7.49M | USD 139.56M |
| FY2023 | USD 7.77M | -USD 116.66M | -USD 109.90M | 39.0% | -14720.25 | USD 24.95M | USD 8.91M | USD 105.53M |
| FY2022 | USD 0 | -USD 110.22M | -USD 146.20M | n/a | -20.01 | USD 120.23M | USD 760.00K | USD 207.18M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-11-06 | USD 79.60M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 114.92M | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 144.73M | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 23.42M | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 22.62M | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 184.32M | n/a | n/a | n/a |
About Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.
ETFs that hold Tonix Pharmaceuticals Holding Corp
US-listed ETFs
Tonix Pharmaceuticals Holding Corp is held by 18 US-listed ETFs, going by the latest portfolios they filed with the SEC. The 8 most traded of them:
| ETF | Weight | Fee |
|---|---|---|
| iShares Russell 2000 ETF (IWM) | 0.01% | 0.19% |
| Vanguard Morningstar Total Stock Market ETF (VTI) | <0.01% | 0.03% |
| iShares Core S&P Total U.S. Stock Market ETF (ITOT) | <0.01% | 0.03% |
| Vanguard Russell 2000 Index Fund ETF Shares (VTWO) | <0.01% | 0.06% |
| iShares Russell 2000 Value ETF (IWN) | 0.01% | 0.24% |
| Vanguard Extended Market Index Fund ETF Shares (VXF) | <0.01% | 0.05% |
| Fidelity Enhanced Small Cap Core ETF (FESM) | 0.02% | 0.28% |
| U.S. Small Cap Portfolio-ETF Class Shares (DFAS) | <0.01% | 0.26% |
Portfolios as filed with the SEC on Form N-PORT, dated May to July 2026. Brokers in the EU generally do not offer US-listed ETFs to retail investors.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Tonix Pharmaceuticals Holding Corp's market cap?
Tonix Pharmaceuticals Holding Corp's market capitalization is USD 79.60M.
What does Tonix Pharmaceuticals Holding Corp do?
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia. It also markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.